Facility-Level Variation in Reported Statin-Associated Side Effects Among Patients with Atherosclerotic Cardiovascular Disease-Perspective from the Veterans Affair Healthcare System.
Atherosclerotic cardiovascular disease
Facility-level variations
Statin-associated side effects
Journal
Cardiovascular drugs and therapy
ISSN: 1573-7241
Titre abrégé: Cardiovasc Drugs Ther
Pays: United States
ID NLM: 8712220
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
accepted:
19
01
2021
pubmed:
2
2
2021
medline:
6
5
2022
entrez:
1
2
2021
Statut:
ppublish
Résumé
Statin-associated side effects (SASEs) can limit statin adherence and present a potential barrier to optimal statin utilization. How standardized reporting of SASEs varies across medical facilities has not been well characterized. We assessed facility-level variation in SASE reporting among patients with atherosclerotic cardiovascular disease receiving care across the Veterans Affairs (VA) healthcare system from October 1, 2014, to September 30, 2015. The facility rates for SASE reporting were expressed as cases per 1000 patients with ASCVD. Facility-level variation was determined using hierarchical regression analysis to calculate median rate ratios (MRR [95% confidence interval]) by first using an unadjusted model and then adjusting for patient, provider, and facility characteristics. Of the 1,248,158 patients with ASCVD included in our study across 130 facilities, 13.7% had at least one SASE reported. Individuals with a history of SASE were less likely to be on a statin at follow-up compared with those without SASE (72.0% vs 80.8%, p < 0.01). The median (interquartile range) facility rate of SASE reported was 140.5 (109.4-167.7) cases per 1000 patients with ASCVD. Significant facility-level variation in the rate of SASE reported was observed: MRR 1.38 (1.33-1.44) in the unadjusted model and MRR 1.56 (1.47-1.65) in the adjusted model. Significant facility-level variation in SASE reporting was found within the VA healthcare system suggesting room for improvement in standardized documentation of SASEs among medical facilities. This has the potential to lead to improvement in statin utilization.
Identifiants
pubmed: 33523335
doi: 10.1007/s10557-021-07148-4
pii: 10.1007/s10557-021-07148-4
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
295-300Subventions
Organisme : Department of Veterans Affairs Health Services Research & Development Service Investigator Initiated Grant
ID : IIR 16-072
Organisme : American Heart Association (US)
ID : 14BGIA20460366
Organisme : American Diabetes Association Clinical Science and Epidemiology award
ID : 1-14- CE-44
Organisme : Houston VA Health Services Research & Development Center for Innovations grant
ID : CIN13-413
Informations de copyright
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.
Références
Cholesterol Treatment Trialists C, Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397–405.
doi: 10.1016/S0140-6736(14)61368-4
Virani SS, Woodard LD, Chitwood SS, Landrum CR, Urech TH, Wang D, et al. Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease. Am Heart J. 2011;162(4):725–32. e1.
doi: 10.1016/j.ahj.2011.07.013
Rodriguez F, Lin S, Maron DJ, Knowles JW, Virani SS, Heidenreich PA. Use of high-intensity statins for patients with atherosclerotic cardiovascular disease in the Veterans Affairs Health System: practice impact of the new cholesterol guidelines. Am Heart J. 2016;182:97–102.
doi: 10.1016/j.ahj.2016.09.007
Pokharel Y, Tang F, Jones PG, Nambi V, Bittner VA, Hira RS, et al. Adoption of the 2013 American College of Cardiology/American Heart Association cholesterol management guideline in cardiology practices Nationwide. JAMA Cardiol. 2017;2(4):361–9.
doi: 10.1001/jamacardio.2016.5922
Mahtta D, Ahmed ST, Ramsey DJ, Akeroyd JM, Lee MT, Rodriguez F, et al. Statin prescription rates, adherence, and associated clinical outcomes among women with PAD and ICVD. Cardiovasc Drugs Ther. 2020;34(6):745–54.
doi: 10.1007/s10557-020-07057-y
Mahtta D, Ramsey DJ, Al Rifai M, Nasir K, Samad Z, Aguilar D, et al. Evaluation of aspirin and statin therapy use and adherence in patients with premature atherosclerotic cardiovascular disease. JAMA Netw Open. 2020;3(8):e2011051.
doi: 10.1001/jamanetworkopen.2020.11051
Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158(7):526–34.
doi: 10.7326/0003-4819-158-7-201304020-00004
Thompson PD, Panza G, Zaleski A, Taylor B. Statin-associated side effects. J Am Coll Cardiol. 2016;67(20):2395–410.
doi: 10.1016/j.jacc.2016.02.071
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019;139(25):e1082–e143.
pubmed: 30586774
Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013;7(5):472–83.
doi: 10.1016/j.jacl.2013.03.001
Statin therapy for the prevention and treatment of cardiovascular disease. In: Program QP, editor. 2020.
Virani SS, Akeroyd JM, Ramsey DJ, Chan WJ, Frazier L, Nasir K, et al. Comparative effectiveness of outpatient cardiovascular disease and diabetes care delivery between advanced practice providers and physician providers in primary care: implications for care under the Affordable Care Act. Am Heart J. 2016;181:74–82.
doi: 10.1016/j.ahj.2016.07.020
Virani SS, Akeroyd JM, Ahmed ST, Krittanawong C, Martin LA, Slagle J, et al. The use of structured data elements to identify ASCVD patients with statin-associated side effects: insights from the Department of Veterans Affairs. J Clin Lipidol. 2019;13(5):797–803. e1.
doi: 10.1016/j.jacl.2019.08.002
Rehman H, Akeroyd JM, Ramsey D, Ahmed ST, Merchant AT, Navaneethan SD, et al. Facility-level variation in diabetes and blood pressure control in patients with diabetes: findings from the Veterans Affairs national database. Clin Cardiol. 2017;40(11):1055–60.
doi: 10.1002/clc.22769
Mahtta D, Ahmed ST, Shah NR, Ramsey DJ, Akeroyd JM, Nasir K, et al. Facility-level variation in cardiac stress test use among patients with diabetes: findings from the Veterans Affairs National Database. Diabetes Care. 2020;43(5):e58–60.
doi: 10.2337/dc19-2160
Virani SS, Woodard LD, Ramsey DJ, Urech TH, Akeroyd JM, Shah T, et al. Gender disparities in evidence-based statin therapy in patients with cardiovascular disease. Am J Cardiol. 2015;115(1):21–6.
doi: 10.1016/j.amjcard.2014.09.041
Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208–15.
doi: 10.1016/j.jacl.2012.03.003
Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management. Eur Heart J. 2015;36(17):1012–22.
doi: 10.1093/eurheartj/ehv043
Ahmed ST, Akeroyd JM, Mahtta D, Street R, Slagle J, Navar AM, et al. Shared decisions: a qualitative study on clinician and patient perspectives on statin therapy and statin-associated side effects. J Am Heart Assoc. 2020;9(22):e017915.
doi: 10.1161/JAHA.120.017915
Wood FA, Howard JP, Finegold JA, Nowbar AN, Thompson DM, Arnold AD, et al. N-of-1 trial of a statin, placebo, or no treatment to assess side effects. N Engl J Med. 2020;383:2182–4.
doi: 10.1056/NEJMc2031173
Lin FY, Dunning AM, Narula J, Shaw LJ, Gransar H, Berman DS, et al. Impact of an automated multimodality point-of-order decision support tool on rates of appropriate testing and clinical decision making for individuals with suspected coronary artery disease: a prospective multicenter study. J Am Coll Cardiol. 2013;62(4):308–16.
doi: 10.1016/j.jacc.2013.04.059
Rosenson RS, Miller K, Bayliss M, Sanchez RJ, Baccara-Dinet MT, Chibedi-De-Roche D, et al. The statin-associated muscle symptom clinical index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability. Cardiovasc Drugs Ther. 2017;31(2):179–86.
doi: 10.1007/s10557-017-6723-4
Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403–14.
doi: 10.1007/s10557-005-5686-z